TWI693071B - 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 - Google Patents
硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 Download PDFInfo
- Publication number
- TWI693071B TWI693071B TW107106359A TW107106359A TWI693071B TW I693071 B TWI693071 B TW I693071B TW 107106359 A TW107106359 A TW 107106359A TW 107106359 A TW107106359 A TW 107106359A TW I693071 B TWI693071 B TW I693071B
- Authority
- TW
- Taiwan
- Prior art keywords
- hepatocellular carcinoma
- patients
- tumor
- invasion
- liver
- Prior art date
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 79
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims abstract description 79
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 238000002271 resection Methods 0.000 title claims abstract description 28
- 229920001542 oligosaccharide Polymers 0.000 title abstract description 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 150000002482 oligosaccharides Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 88
- 230000004083 survival effect Effects 0.000 claims abstract description 54
- 230000009545 invasion Effects 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 210000004185 liver Anatomy 0.000 claims abstract description 31
- 230000009790 vascular invasion Effects 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims description 60
- 229940079593 drug Drugs 0.000 claims description 51
- 238000001356 surgical procedure Methods 0.000 claims description 19
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 9
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 210000004204 blood vessel Anatomy 0.000 claims description 8
- 230000002980 postoperative effect Effects 0.000 claims description 8
- 241000700721 Hepatitis B virus Species 0.000 claims description 7
- 238000012752 Hepatectomy Methods 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 5
- 229940124405 anti-hepatitis b virus drug Drugs 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 238000001647 drug administration Methods 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 40
- 229940068196 placebo Drugs 0.000 description 40
- 238000004458 analytical method Methods 0.000 description 32
- 230000034994 death Effects 0.000 description 23
- 231100000517 death Toxicity 0.000 description 23
- 230000000694 effects Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- 230000001681 protective effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 238000009098 adjuvant therapy Methods 0.000 description 9
- 230000001186 cumulative effect Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000009499 grossing Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 6
- 238000002591 computed tomography Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000036962 time dependent Effects 0.000 description 6
- 230000002668 anti-heparin effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- -1 manganese sulfide phosphate Chemical compound 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000000491 multivariate analysis Methods 0.000 description 4
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 4
- 238000007473 univariate analysis Methods 0.000 description 4
- 108010022901 Heparin Lyase Proteins 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000007775 late Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 101710090983 T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960001997 adefovir Drugs 0.000 description 2
- 229960003205 adefovir dipivoxil Drugs 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 229940124404 anti-hepatitis c virus drug Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- 229960000980 entecavir Drugs 0.000 description 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000009022 nonlinear effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960003930 peginterferon alfa-2a Drugs 0.000 description 2
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 229960005311 telbivudine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 2
- 229960004556 tenofovir Drugs 0.000 description 2
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710114790 Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 238000012351 Integrated analysis Methods 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 102000007295 Mucin-3 Human genes 0.000 description 1
- 108010008701 Mucin-3 Proteins 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000010109 chemoembolization Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical group COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- OBMNJSNZOWALQB-NCQNOWPTSA-N grazoprevir Chemical compound O=C([C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCCC1=NC3=CC=C(C=C3N=C1O2)OC)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C OBMNJSNZOWALQB-NCQNOWPTSA-N 0.000 description 1
- 229960002914 grazoprevir Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000012002 interactive response technology Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000009021 linear effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229960000518 ombitasvir Drugs 0.000 description 1
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 description 1
- 229960002754 paritaprevir Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000034655 secondary growth Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465170P | 2017-03-01 | 2017-03-01 | |
| US62/465,270 | 2017-03-01 | ||
| US201762504552P | 2017-05-11 | 2017-05-11 | |
| US62/504,552 | 2017-05-11 | ||
| US201762551770P | 2017-08-29 | 2017-08-29 | |
| US62/551,770 | 2017-08-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201840324A TW201840324A (zh) | 2018-11-16 |
| TWI693071B true TWI693071B (zh) | 2020-05-11 |
Family
ID=63357147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107106359A TWI693071B (zh) | 2017-03-01 | 2018-02-26 | 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10842804B2 (enExample) |
| JP (1) | JP6948080B2 (enExample) |
| KR (1) | KR102265159B1 (enExample) |
| CN (1) | CN110381953A (enExample) |
| TW (1) | TWI693071B (enExample) |
| WO (1) | WO2018157762A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113160911A (zh) * | 2021-02-26 | 2021-07-23 | 杭州臻合健康科技有限公司 | 一种用于术前肝功能耐受性分析的评估系统 |
| CN117476246B (zh) * | 2023-12-25 | 2024-04-19 | 福建大数据一级开发有限公司 | 基于多类型复发事件的患者生存分析方法、介质及装置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005219456B2 (en) * | 2004-03-04 | 2011-04-07 | Progen Pharmaceuticals Limited | Sulfated oligosaccharide derivatives |
| KR20140050605A (ko) | 2011-06-09 | 2014-04-29 | 메디젠 바이오테크놀로지 코프 | 간암의 재발, 악화 또는 전이 억제용 의약조성물 |
-
2018
- 2018-02-08 US US15/892,343 patent/US10842804B2/en active Active
- 2018-02-24 CN CN201880014397.6A patent/CN110381953A/zh active Pending
- 2018-02-24 JP JP2019547371A patent/JP6948080B2/ja active Active
- 2018-02-24 WO PCT/CN2018/077105 patent/WO2018157762A1/en not_active Ceased
- 2018-02-24 KR KR1020197028654A patent/KR102265159B1/ko active Active
- 2018-02-26 TW TW107106359A patent/TWI693071B/zh active
Non-Patent Citations (4)
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190120339A (ko) | 2019-10-23 |
| KR102265159B1 (ko) | 2021-06-17 |
| WO2018157762A1 (en) | 2018-09-07 |
| US20180250317A1 (en) | 2018-09-06 |
| JP6948080B2 (ja) | 2021-10-13 |
| US10842804B2 (en) | 2020-11-24 |
| JP2020509035A (ja) | 2020-03-26 |
| CN110381953A (zh) | 2019-10-25 |
| TW201840324A (zh) | 2018-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Willemze et al. | Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| US20250154274A1 (en) | Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment | |
| US10340031B2 (en) | Systems and methods for identifying cancer treatments from normalized biomarker scores | |
| AU2007213920B2 (en) | Treatment of metastatic breast cancer | |
| BR112019015011A2 (pt) | combinações de cabozantinibe e atezolizumabe para tratar câncer | |
| CN107750165A (zh) | 借助塞里班土单抗的组合治疗 | |
| TWI693071B (zh) | 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途 | |
| TW202043273A (zh) | 用於晚期實性瘤癌症之治療性ｒｎａ | |
| Qiu et al. | The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions | |
| Li et al. | Immune myocarditis induced by sintilimab therapy: A case report | |
| Zhang et al. | A Phase II Randomized Trial of Individualized Neoantigen Peptide Vaccine Combined with Unusual Radiotherapy (iNATURE) in Advanced Solid Tumors | |
| US20250186584A1 (en) | Methods of treating biliary tract cancer using anti-pd-l1 antibody in combination with chemotherapy | |
| Zhou et al. | Definition of a new blood cell count (BCT) score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of 4 multicenter clinical trials | |
| Subudhi | A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC) | |
| Leemans | Short title NeoNivo EudraCT number 2018-002643-28 Version 9 Date 11-12-2019 Principal investigators C. Willemien Menke-van der Houven van Oordt, MD PhD | |
| CONFIDENTIAL et al. | A Phase 1b Study to Evaluate safety and clinical activity of Pembrolizumab (MK-3475) in combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC)-(KEYNOTE 173) | |
| WO2024216390A1 (en) | Methods to treat glioma in subjects with defined tumour microenvironment | |
| Sundahl et al. | Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma | |
| Coffey et al. | Management of early breast cancer in women over 90: A 10 year experience | |
| Vavolizza | MEL 64 | |
| Lead et al. | Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects with Advanced Hepatocellular Carcinoma–A Phase II Study (PEMRAD) Coordinating Center: Princess Margaret Cancer Centre 610 University Avenue Toronto, ON M5G 2M9 | |
| code VHIO19001 | Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC) | |
| EA041548B1 (ru) | Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей | |
| CN102961747A (zh) | 转移性乳腺癌的治疗 |